Scarica l'app Stockscreener
0.00
100.00%
-5.54
Dopo l'orario di chiusura:
5.54
5.54
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.54
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$301.29M
Reddito:
$80.75M
Utile/perdita netta:
$-20.13M
Rapporto P/E:
0.00
EPS:
-2.1622
Flusso di cassa netto:
$-89.79M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$5.65
Alimera Sciences Inc Stock (ALIM) Company Profile
Nome
Alimera Sciences Inc
Settore
Telefono
678-990-5740
Indirizzo
6310 TOWN SQUARE, ALPHARETTA, GA
Confronta ALIM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALIM
Alimera Sciences Inc
|
0.00 | 301.29M | 80.75M | -20.13M | -89.79M | -2.1622 |
|
ZTS
Zoetis Inc
|
172.24 | 77.71B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.52 | 43.05B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.32 | 42.23B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.06 | 19.33B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
152.42 | 15.43B | 2.24B | 385.90M | 440.10M | 3.73 |
Alimera Sciences Inc Stock (ALIM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-28 | Iniziato | Craig Hallum | Buy |
| 2017-04-27 | Iniziato | Rodman & Renshaw | Buy |
| 2014-11-17 | Iniziato | Summer Street Research | Buy |
| 2014-09-29 | Reiterato | Northland Capital | Outperform |
| 2013-10-28 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2013-10-08 | Iniziato | Northland Capital | Outperform |
| 2011-11-14 | Downgrade | Rodman & Renshaw | Mkt Outperform → Mkt Perform |
| 2010-12-27 | Reiterato | Oppenheimer | Outperform |
| 2010-10-11 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2010-06-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Alimera Sciences Inc Borsa (ALIM) Ultime notizie
Alimera Sciences Announces Data from 19 Iluvien(R) Studies to be Presented at 2018 ARVO - ACCESS Newswire
ALIMERA SCIENCES INC to Host Earnings Call - ACCESS Newswire
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Actinic Keratosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
ANIPANI Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity - The Manila Times
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.ALIM - GuruFocus.com
Autoimmune Uveitis Market Will Accelerate Rapidly with - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eye Inflammation Treatment Market Overall Study Report - openPR
Diabetic Macular Edema Market Key Players AnalysisNovartis - openPR
Ophthalmic Steroids Drugs Market 2024-2031 Porter's Five - openPR
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance - GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% - GlobeNewswire
ANI Pharmaceuticals introduces generic Estradiol Gel By Investing.com - Investing.com South Africa
ANI Pharmaceuticals introduces generic Estradiol Gel - Investing.com
ANI Pharmaceuticals to Present New Data Highlighting - GlobeNewswire
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 - StockTitan
ANI Pharmaceuticals price target raised to $62 from $60 at Truist - Yahoo Finance
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market - Seeking Alpha
StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM) - Defense World
Stonepine Capital Management LLC Sells 539,256 Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Defense World
20,394 Shares in Alimera Sciences, Inc. (NASDAQ:ALIM) Acquired by Rhumbline Advisers - Defense World
Alimera Sciences (NASDAQ:ALIM) Coverage Initiated at StockNews.com - Defense World
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - StockTitan
On the Move: Mergers, Management Moves, and More - Community News
Glazer Capital LLC Makes New $3.07 Million Investment in Alimera Sciences, Inc. (NASDAQ:ALIM) - Defense World
Allarity Therapeutics, Inc Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Allarity Therapeutics, - Longview News-Journal
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
ALLR CLASS ACTION REMINDERRobbins LLP Reminds - GlobeNewswire
Great Point Partners LLC Increases Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Stocks Under $20: Arlo Technologies, Applied Optoelectronics - Schaeffers Research
Allison Transmission (NYSE:ALSN) Reaches New 1-Year High at $92.93 - MarketBeat
Market Watch: Alignment Healthcare Inc (ALHC)’s Noteworthy Drop, Closing at 10.98 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
A stock that deserves closer examination: Allarity Therapeutics Inc (ALLR) - US Post News
Berkley W R Corp Purchases New Shares in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) - MarketBeat
Market Momentum: Allarity Therapeutics Inc (ALLR) Registers a 1.36 Increase, Closing at 2.24 - The Dwinnex
Intech Investment Management LLC Has $1.74 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Rhumbline Advisers Purchases 87 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Bubble
Elevai Labs shares tumble on pricing of new stock offering - The Business Journals
Alector (NASDAQ:ALEC) Shares Down 5.6% - Defense World
Integral Health Asset Management LLC Buys 20,000 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ALLR INVESTOR ALERT: Edelson Lechtzin LLP Urges Allarity - GlobeNewswire
Alignment Healthcare (NASDAQ:ALHC) Shares Gap Down to $11.43 - Defense World
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Wall Street analysts’ outlook for Arcellx Inc (ACLX) - SETE News
In the Green: Longboard Pharmaceuticals Inc (LBPH) Closes at 33.89, Up/Down 1.47 from Previous Day - The Dwinnex
Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga
Alimera Sciences Inc Azioni (ALIM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):